What's Behind Pacific Biosciences of California's Stock Rally Today?
Shares of Pacific Biosciences of California (NASDAQ: PACB) are on the rise again. This is the third trading session in a row that the stock has marched upwards since announcing record revenues and a big order for its next-generation genomic sequencers last week. The stock has tacked on a 11.7% gain as of 2:45 p.m. EDT on Monday.
The stock has risen about 40% since Aug. 2. After the bell that afternoon, Pacific Biosciences announced a new agreement with genomic services giant Novogene. The latter company agreed to double its Sequel-driven sequencing capacity with a purchase of 10 more systems.
Image source: Getty Images.
Source: Fool.com
Pacific Biosciences of California Inc. Aktie
1,53 €
-12,02 %
Die Community sieht Pacific Biosciences of California Inc. leicht positiv: Mehr Buy- als Sell-Einschätzungen.
Bei einem durchschnittlichen Kursziel von 9 € für Pacific Biosciences of California Inc., wäre dies mehr als eine Verdopplung des aktuellen Kurses von 1.53 €.
